{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:37:32Z","timestamp":1791430652000,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Hrvatska Zaklada za Znanost","doi-asserted-by":"publisher","award":["IP-2019-04-3684"],"award-info":[{"award-number":["IP-2019-04-3684"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.prp.2024.155096","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T12:32:53Z","timestamp":1704371573000},"page":"155096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["PRAME expression and its prognostic significance in invasive breast carcinoma"],"prefix":"10.1016","volume":"254","author":[{"given":"Lea","family":"Kor\u0161a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Abramovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucija","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Milo\u0161evi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Podolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Prutki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Maru\u0161i\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155096_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2024.155096_bib2","article-title":"Tumor heterogeneity in breast cancer","volume":"4","author":"Turashvili","year":"2017","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.prp.2024.155096_bib3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.prp.2024.155096_bib4","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.prp.2024.155096_bib5","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155096_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000433590","article-title":"14th St. Gallen international breast cancer conference 2015: evidence, controversies, consensus - primary therapy of early breast cancer: opinions expressed by German experts","volume":"10","author":"Jackisch","year":"2015","journal-title":"Breast Care"},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000430488","article-title":"St. Gallen\/Vienna 2015: a brief summary of the consensus discussion","volume":"10","author":"Gnant","year":"2015","journal-title":"Breast Care"},{"key":"10.1016\/j.prp.2024.155096_bib8","article-title":"Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications","author":"Sher","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","article-title":"Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor","volume":"6","author":"Ikeda","year":"1997","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2024.155096_bib11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","article-title":"PRAME Expression in melanocytic tumors","volume":"42","author":"Lezcano","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"12","key":"10.1016\/j.prp.2024.155096_bib12","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41379-019-0335-4","article-title":"Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas","volume":"32","author":"Toyama","year":"2019","journal-title":"Mod. Pathol."},{"issue":"10","key":"10.1016\/j.prp.2024.155096_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bjo.2009.167445","article-title":"Expression of MCSP and PRAME in conjunctival melanoma","volume":"94","author":"Westekemper","year":"2010","journal-title":"Br. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.prp.2024.155096_bib14","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2217\/bmm.12.65","article-title":"The cancer testis antigen PRAME as a biomarker for solid tumor cancer management","volume":"6","author":"Goodison","year":"2012","journal-title":"Biomark. Med."},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.prp.2024.155096_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.prp.2024.155096_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1158\/2326-6066.CIR-13-0088","article-title":"Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers","volume":"2","author":"Yao","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.prp.2024.155096_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.breast.2018.08.106","article-title":"Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: an indication to immunotherapy?","volume":"42","author":"Tessari","year":"2018","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.breast.2019.12.002","article-title":"Expression of tumor-associated antigens in breast cancer subtypes","volume":"49","author":"Curigliano","year":"2020","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.prp.2024.155096_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12770","article-title":"The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer","volume":"53","author":"Xu","year":"2020","journal-title":"Cell Prolif."},{"issue":"8","key":"10.1016\/j.prp.2024.155096_bib21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1177\/10668969211012085","article-title":"Immunohistochemical detection of cancer-testis antigen PRAME","volume":"29","author":"Lezcano","year":"2021","journal-title":"Int. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155096_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155096_bib23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155096_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0901-4","article-title":"Applying the new guidelines of HER2 testing in breast cancer","volume":"22","author":"Zhang","year":"2020","journal-title":"Curr. Oncol. Rep."},{"issue":"9938","key":"10.1016\/j.prp.2024.155096_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.prp.2024.155096_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1757-3","article-title":"PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer","volume":"17","author":"Al-Khadairi","year":"2019","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.prp.2024.155096_bib27","doi-asserted-by":"crossref","unstructured":"Dieci M.V., Mathieu M.C., Guarneri V., Conte P., Delaloge S., Andre F., et al. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Two Phase III Randomized Adjuvant Breast Cancer Trials. Ann Oncol: Off J Eur Soc Med Oncol 26:1698\u20131704. doi:10.1093\/annonc\/mdv239.","DOI":"10.1093\/annonc\/mdv239"},{"key":"10.1016\/j.prp.2024.155096_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","author":"Adams","year":"2014","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.prp.2024.155096_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2024.155096_bib30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2024.155096_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/cancers15030767","article-title":"Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment","volume":"15","author":"Valenza","year":"2023","journal-title":"Cancers"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:57:30Z","timestamp":1767167850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":31,"alternative-id":["S0344033824000074"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155096","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PRAME expression and its prognostic significance in invasive breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155096"}}